TG THERAPEUTICS INC (TGTX)
US88322Q1085 - Common Stock
We assign a fundamental rating of 4 out of 10 to TGTX. TGTX was compared to 569 industry peers in the Biotechnology industry. The financial health of TGTX is average, but there are quite some concerns on its profitability. TGTX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
TGTX had negative earnings in the past year.
TGTX had a negative operating cash flow in the past year.
TGTX had negative earnings in 4 of the past 5 years.
TGTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TGTX has a better Return On Assets (-2.45%) than 91.01% of its industry peers.
TGTX's Return On Equity of -7.48% is amongst the best of the industry. TGTX outperforms 91.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.45% | ||
| ROE | -7.48% | ||
| ROIC | N/A |
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TGTX has a better Gross Margin (88.32%) than 91.36% of its industry peers.
The Profit Margin and Operating Margin are not available for TGTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
TGTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TGTX has an improved debt to assets ratio.
2.2 Solvency
TGTX has an Altman-Z score of 5.98. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.98, TGTX belongs to the best of the industry, outperforming 81.66% of the companies in the same industry.
TGTX has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.27, TGTX is doing worse than 79.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.98 |
ROIC/WACCN/A
WACC10.46%
2.3 Liquidity
TGTX has a Current Ratio of 4.59. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Current ratio (4.59) which is comparable to the rest of the industry.
TGTX has a Quick Ratio of 3.91. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.91, TGTX perfoms like the industry average, outperforming 47.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.71%, which is quite impressive.
The Revenue has grown by 39.51% in the past year. This is a very strong growth!
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 335.01% yearly.
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%
3.2 Future
Based on estimates for the next years, TGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 229.97% on average per year.
The Revenue is expected to grow by 41.13% on average over the next years. This is a very strong growth
EPS Next Y1407.36%
EPS Next 2Y894.69%
EPS Next 3Y468.36%
EPS Next 5Y229.97%
Revenue Next Year42.48%
Revenue Next 2Y53%
Revenue Next 3Y47.78%
Revenue Next 5Y41.13%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 35.45, TGTX can be considered very expensive at the moment.
TGTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 93.30% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.00. TGTX is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 35.45 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 468.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y894.69%
EPS Next 3Y468.36%
5. Dividend
5.1 Amount
No dividends for TGTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TG THERAPEUTICS INC
NASDAQ:TGTX (11/22/2024, 8:08:16 PM)
After market: 35.5 +0.43 (+1.23%)35.07
+0.52 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.46B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 35.45 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.45% | ||
| ROE | -7.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.32% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.59 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y1407.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y